The prostate enlarges primarily because of hormonal shifts that begin in a man’s 30s and accelerate with age. By the time men reach their 50s, about half have some degree of benign prostatic hyperplasia (BPH), and that figure climbs to roughly 80% in men over 70. While aging is the single biggest driver, the process involves several overlapping forces: changing hormone levels, chronic low-grade inflammation, metabolic health, genetics, and the prostate’s unique anatomy.
How Hormones Drive Prostate Growth
Testosterone circulating in the bloodstream gets converted inside prostate cells into a much more potent form called DHT. An enzyme called 5-alpha reductase handles this conversion, and DHT is the principal hormone that binds to receptors inside the prostate cell nucleus and signals cells to grow. This process happens throughout a man’s life, but the balance of hormones around the prostate changes significantly with age.
As men get older, overall testosterone levels gradually decline. Estrogen levels, however, stay relatively constant. The net effect is a rising ratio of estrogen to testosterone in the blood. This shifting balance is closely linked to BPH development. Estrogen appears to stimulate a specific type of receptor in prostate tissue that promotes cell proliferation, inflammation, and the formation of the small nodules that make up an enlarged prostate. So it’s not simply “too much testosterone” causing the problem. It’s the interplay between declining testosterone, steady estrogen, and the continued local production of DHT inside the gland itself.
Where Enlargement Happens and Why It Causes Symptoms
The prostate has several distinct zones, and BPH originates in the transition zone, the ring of tissue that directly surrounds the urethra. This is what makes even modest growth so disruptive. A prostate that expands outward in a different zone might go unnoticed for years, but growth in the transition zone squeezes the urinary channel like a clamp on a garden hose.
That compression, combined with nerve signaling changes in the prostate and bladder, produces the cluster of symptoms most men recognize: a weak or interrupted urine stream, difficulty starting urination, the feeling that the bladder never fully empties, frequent trips to the bathroom (especially at night), and post-urination dribbling. The severity of symptoms doesn’t always match the size of the prostate. Some men with significantly enlarged glands have mild symptoms, while others with modest enlargement experience major disruption.
Chronic Inflammation as a Growth Trigger
Researchers have found that ongoing, low-level inflammation inside the prostate plays a bigger role in enlargement than previously understood. Immune signaling molecules accumulate in prostate tissue and create a cycle of tissue injury and repair that gradually increases prostate volume.
Here’s how it works: inflammatory signals stimulate the production of growth factors, particularly fibroblast growth factor (FGF-2), which drives abnormal cell proliferation. At the same time, immune cells release additional chemical signals that promote smooth muscle contraction within the prostate, worsening urinary obstruction beyond what the physical size of the gland alone would cause. This inflammation-driven remodeling helps explain why some prostates grow faster than others and why anti-inflammatory approaches can sometimes reduce symptoms.
What triggers the inflammation in the first place isn’t always clear. Possible culprits include bacterial infections (past or present), urine reflux into prostate ducts, hormonal imbalances, and dietary factors. Regardless of the initial trigger, the resulting inflammatory environment becomes self-sustaining, feeding continued growth over years and decades.
Metabolic Health and Prostate Size
Your overall metabolic health has a measurable effect on prostate size. Insulin resistance, the condition where cells stop responding efficiently to insulin and the body compensates by producing more, is consistently linked to larger prostates. In one Swedish study, men with metabolic syndrome (a combination of obesity, high blood pressure, abnormal cholesterol, and insulin resistance) had an average prostate volume of 49 milliliters compared to 28.5 milliliters in men without it.
Data from the large REDUCE trial showed that men with the highest levels of insulin resistance had significantly larger prostates at every time point measured over four years. The likely mechanism involves excess insulin triggering elevated levels of a growth-promoting hormone called IGF-1, which directly stimulates prostate cell growth. High insulin also increases sympathetic nervous system activity and alters how the body processes steroid hormones, both of which can compound the problem.
The practical implication: sedentary lifestyle, obesity, type 2 diabetes, and excessive alcohol consumption are all recognized risk factors for BPH. These are also the most modifiable ones. Men who manage their weight and insulin sensitivity may be able to slow prostate growth, though research on whether this reverses existing enlargement is still limited.
Genetics and Family History
Family history is a genuine risk factor, particularly for men who develop BPH at a younger age. A case-control study found that male relatives of men with early-onset BPH (before age 64) had a 66% cumulative lifetime risk of needing prostate surgery, compared to just 17% in control families. Brothers of affected men faced a sixfold increase in risk.
Segregation analysis suggested that a dominantly inherited gene is the most likely explanation for this clustering, meaning a single copy of the gene passed from one parent can be enough to raise risk. This genetic predisposition doesn’t guarantee severe symptoms, but it does mean the process may start earlier and progress faster in some men. If your father or brother needed treatment for an enlarged prostate before age 65, your own risk is meaningfully elevated.
BPH and Prostate Cancer: What the Data Shows
BPH is not prostate cancer, and the two conditions arise in different parts of the gland. BPH develops in the transition zone; most prostate cancers originate in the peripheral zone. However, the older reassurance that BPH carries no connection to cancer risk has been complicated by newer evidence.
A large prospective study using UK Biobank data found that men with BPH had a 28 to 30% higher risk of developing prostate cancer compared to men without BPH, even after adjusting for other health conditions. Further analysis using a method designed to test for cause-and-effect relationships (Mendelian randomization) supported a small but real causal link. This doesn’t mean BPH transforms into cancer. It likely reflects shared underlying biology: overlapping hormonal drivers, chronic inflammation, and growth factor signaling that create a tissue environment where both conditions become more probable. The elevated risk is modest, but it reinforces the value of continued screening and monitoring even when a prostate diagnosis is clearly benign.
Why It Gets Worse With Age
Prostate enlargement is progressive because every contributing factor intensifies over time. DHT production inside the gland continues even as blood testosterone drops. The estrogen-to-testosterone ratio keeps climbing. Inflammatory damage accumulates. Metabolic health tends to worsen with age. And the growth factor signaling pathways that maintain normal prostate tissue gradually become dysregulated, tipping from maintenance into overgrowth.
The prostate is one of the few organs that continues growing throughout adulthood. Most men’s prostates roughly double in size between age 20 and age 50, and in many men, growth continues well beyond that. The combination of a gland that never stops expanding and an anatomical position wrapped around the urethra is why BPH eventually affects the vast majority of older men, even those in otherwise excellent health.